Your session is about to expire
← Back to Search
Other
CX-904 for Advanced Solid Cancers
Phase 1
Recruiting
Research Sponsored by CytomX Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group performance status of 0 or 1
Histologically confirmed metastatic or locally advanced unresectable solid tumor. Must have received prior standard therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing CX-904, a new medicine that helps the immune system fight advanced cancers that can't be removed by surgery. It works by connecting immune cells to cancer cells, making it easier for the body to attack the cancer.
Who is the study for?
This trial is for adults with advanced solid tumors that can't be surgically removed and have spread. They should have tried standard treatments already, not have serious heart issues or autoimmune diseases, and agree to use effective birth control. Those with small, symptom-free brain metastases may join after special consideration.
What is being tested?
The study tests CX-904's safety and effectiveness in treating advanced solid tumors. It will assess how the body processes the drug (PK), its impact on the tumor (PD), tolerability at different doses, and any potential benefits in shrinking or controlling tumor growth.
What are the potential side effects?
Since this is a first-in-human study for CX-904, specific side effects are unknown but could include typical reactions seen with cancer drugs such as nausea, fatigue, allergic reactions, blood count changes, organ inflammation or other unexpected symptoms.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and I've had standard treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Patients Experiencing Dose-limiting Toxicity
Secondary study objectives
Disease Control Rate (DCR)
Duration of Response (DOR)
Investigator-assessed Progression-Free Survival (PFS)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CX-904Experimental Treatment1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for solid tumors include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy works by killing rapidly dividing cells, including cancer cells, but can also affect normal cells, leading to side effects.
Targeted therapies, such as tyrosine kinase inhibitors, specifically target molecular pathways crucial for tumor growth and survival, thereby minimizing damage to normal cells. Immunotherapy, including immune checkpoint inhibitors, enhances the body's immune response against cancer cells.
Novel agents like CX-904, which are being studied for their ability to inhibit tumor growth or progression, represent a promising approach by potentially offering more precise and effective treatment options with fewer side effects. These mechanisms are crucial for solid tumor patients as they aim to improve survival rates and quality of life by effectively controlling tumor growth while minimizing adverse effects.
Find a Location
Who is running the clinical trial?
CytomX TherapeuticsLead Sponsor
8 Previous Clinical Trials
905 Total Patients Enrolled
Monika Vainorius, M.D.Study DirectorCytomX Therapeutics, Inc
2 Previous Clinical Trials
258 Total Patients Enrolled
Lawrence LuStudy DirectorCytomX Therapeutics, Inc
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had cancer within the last 2 years, but it's considered cured and low risk of coming back.I have small brain tumors (≤1 cm) that need treatment.I am fully active or can carry out light work.My cancer is advanced, cannot be surgically removed, and I've had standard treatment.
Research Study Groups:
This trial has the following groups:- Group 1: CX-904
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.